Cargando…

Mutationally-activated PI3’-kinase-α promotes de-differentiation of lung tumors initiated by the BRAF(V600E) oncoprotein kinase

Human lung adenocarcinoma exhibits a propensity for de-differentiation, complicating diagnosis and treatment, and predicting poorer patient survival. In genetically engineered mouse models of lung cancer, expression of the BRAF(V600E) oncoprotein kinase initiates the growth of benign tumors retainin...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Veen, J Edward, Scherzer, Michael, Boshuizen, Julia, Chu, Mollee, Liu, Annie, Landman, Allison, Green, Shon, Trejo, Christy, McMahon, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2019
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711745/ https://www.ncbi.nlm.nih.gov/pubmed/31452510 http://dx.doi.org/10.7554/eLife.43668

Ejemplares similares

BRAF(V600E) cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis
por: Sakamoto, Naoya, et al.
Publicado: (2017)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

The yin–yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF
por: Kiel, Christina, et al.
Publicado: (2016)

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
por: Gibney, Geoffrey T, et al.
Publicado: (2015)

The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets
por: Saurabh, Kumar, et al.
Publicado: (2014)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

BRAF(V600E) induces reversible mitotic arrest in human melanocytes via microRNA-mediated suppression of AURKB
por: McNeal, Andrew S, et al.
Publicado: (2021)

BRAF V600E potentially determines “Oncological Resectability” for “Technically Resectable” colorectal liver metastases
por: Kobayashi, Shin, et al.
Publicado: (2021)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
por: Tahiri, Andliena, et al.
Publicado: (2013)

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
por: Kemper, Kristel, et al.
Publicado: (2016)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
por: Moser, Justin C., et al.
Publicado: (2019)

Characterization of uridine-cytidine kinase like-1 nucleoside kinase activity and its role in tumor growth
por: Matchett, Emily C., et al.
Publicado: (2022)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF(V600E)-Driven Lung Tumorigenesis
por: Vaishnavi, Aria, et al.
Publicado: (2022)

BRAF(V600E) Expression Is Homogenous and Associated with Nonrecurrent Disease and Better Survival in Primary Melanoma
por: Naimy, Soraya, et al.
Publicado: (2023)

Cross-Regulation between Oncogenic BRAF(V600E) Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma
por: Lee, Seong Jin, et al.
Publicado: (2011)

BRAF(V600E) inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells
por: Sueda, Toshinori, et al.
Publicado: (2016)

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
por: Liu, Rengyun, et al.
Publicado: (2018)

Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting
por: Hilhorst, Riet, et al.
Publicado: (2023)

Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors
por: Dankner, Matthew, et al.
Publicado: (2022)

Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway
por: Naeem, Aisha, et al.
Publicado: (2022)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF(V600E) mutation test on fine‐needle aspiration specimens of thyroid nodules: Clinical correlations for 4600 patients
por: Chen, Huang, et al.
Publicado: (2021)

BRAF (V600E)/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Colle, Raphael, et al.
Publicado: (2023)

A comprehensive and perspective view of oncoprotein SET in cancer
por: Bayarkhangai, Buuvee, et al.
Publicado: (2018)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Glycogen synthase kinase 3β promotes osteosarcoma invasion and migration via regulating PTEN and phosphorylation of focal adhesion kinase
por: Mai, Wei, et al.
Publicado: (2021)

Oncogenic BRAF(V600E) induces microglial proliferation through extracellular signal-regulated kinase and neuronal death through c-Jun N-terminal kinase
por: Ye, Qing, et al.
Publicado: (2022)

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF (V600E)-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
por: Tabernero, Josep, et al.
Publicado: (2023)

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells
por: Halaban, Ruth, et al.
Publicado: (2010)

Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF(V600E)-mutant melanoma
por: Harris, Antoneicka L., et al.
Publicado: (2017)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAF(V600E)-Mutant Colorectal Cancer
por: Napolitano, Stefania, et al.
Publicado: (2023)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma
por: Janostiak, Radoslav, et al.
Publicado: (2019)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
por: Tran, Khanh B., et al.
Publicado: (2021)

The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress
por: Liu, Yanan, et al.
Publicado: (2022)

BRAF(V600E) mutation analysis in fine‐needle aspiration cytology specimens for diagnosis of thyroid nodules: The influence of false‐positive and false‐negative results
por: Zhao, Chong‐Ke, et al.
Publicado: (2019)

Diminished WNT → β-catenin → c-MYC signaling is a barrier for malignant progression of BRAF(V600E)-induced lung tumors
por: Juan, Joseph, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_g3qnfjv7adf8novi2lmb9b8ar3